Given the severity of my predictions, I'm often asked what steps I would take if I were vaccinated against Covid-19 (C-19). Well, here's what I would do: I'd ensure I promptly acquire enough ivermectin to last for about three months. As soon as any heavily C-19 vaccinated country experiences a significant surge in cases of enhanced severe C-19 disease, I'd promptly begin taking ivermectin at a relatively high dose, i.e., 0.5-0.6 mg/kg, once daily. Additionally, I'd make sure to get myself re-vaccinated with a live attenuated measles vaccine (if combined with other live attenuated viruses like mumps and rubella, that would be acceptable too). Drawing from my past research on Natural Killer (NK) cell vaccines, I believe there's a theoretical possibility that cell-based innate immune training gained from exposure to measles could offer C-19 vaccinees at least some first-line protection against coronaviruses (while C-19 vaccinees are unlikely to mount any meaningful immune response against live attenuated coronaviruses at this 'chronic' stage of the pandemic!). While innate immune imprinting can last for a while, ideally, I'd prefer to receive the measles vaccine closer to the onset of the anticipated hyperacute phase of the pandemic. Of course, one might consider self-isolation, but given the airborne transmission and high inherent infectiousness of the new coronavirus I expect to emerge soon, this may not be very effective. The prophylactic use of ivermectin combined with the measles vaccine is, of course, not a medical recommendation but merely a consideration that every C-19 vaccinated individual might want to ponder, particularly since both interventions have well-documented safety profiles. However, before using ivermectin, it's essential to verify that it won't have any adverse interactions with other medications one may be taking. On the other hand, vaccination against measles should be avoided in individuals who are ill, pregnant, or have a compromised innate immune system (note: ‘untrained’ does not imply weakened!).
Here is the link with further information on the potential prophylactic use of ivermectin in the event of the emergence of a highly virulent coronavirus: https://notesfromthesocialclinic.org/prophylactic-use-of-ivermectin/
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.
Email: info@voiceforscienceandsolidarity.org
.svg){kind=small}
